Kirtschig, G. and Kinberger, M. and Kreuter, A. and Simpson, R. and Guenthert, A. and van Hees, C. and Becker, K. and Ramakers, M. J. and Corazza, M. and Mueller, S. and von Seitzberg, S. and Boffa, M. J. and Stein, R. and Barbagli, G. and Chi, C. C. and Dauendorffer, J. N. and Fischer, B. and Gaskins, M. and Hiltunen-Back, E. and Hoefinger, A. and Koellmann, N. H. and Kuehn, H. and Larsen, H. K. and Lazzeri, M. and Mendling, W. and Nikkels, A. F. and Promm, M. and Rall, K. K. and Regauer, S. and Sardy, M. and Sepp, N. and Thune, T. and Tsiogka, A. and Vassileva, S. and Voswinkel, L. and Woelber, L. and Werner, R. N. (2024) EuroGuiderm guideline on lichen sclerosus-Treatment of lichen sclerosus. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 38 (10). pp. 1874-1909. ISSN 0926-9959, 1468-3083
Full text not available from this repository. (Request a copy)Abstract
Introduction: Lichen sclerosus (LS) is an inflammatory skin disease affecting all ages. LS typically involves the anogenital site where it causes itching and soreness; it may lead to sexual and urinary dysfunction in females and males; however, it may be asymptomatic. First signs of LS are usually a whitening of the genital skin, sometimes preceded by redness and oedema; fissuring, scarring, shrinkage and fusion of structures may follow in its course. LS is associated with an increased risk of genital cancer. LS has a huge impact on the quality of life of affected patients, and it is important to raise more awareness of this not uncommon disease in order to diagnose and treat it early. Objectives: The guideline intends to provide guidance on the diagnostic of LS (part 1), highlight important aspects in the care of LS patients, generate recommendations and treatment algorithms (part 2) on topical, interventional and surgical therapy, based on the latest evidence, provide guidance in the management of LS patients during pregnancy, provide guidance for the follow-up of patients with LS and inform about new developments and potential research aspects. Materials and Methods: The guideline was developed in accordance with the EuroGuiDerm Methods Manual v1.3 https://www.edf.one/de/home/Guidelines/EDF-EuroGuiDerm.html. The wording of the recommendations was standardized (as suggested by the GRADE Working Group). The guideline development group is comprised of 34 experts from 16 countries, including 5 patient representatives. Results: Ultrapotent or potent topical corticosteroids in females and males, adults and children remain gold standard of care for genital LS; co-treatment with emollients is recommended. If standard treatment fails in males, a surgical intervention is recommended, complete circumcision may cure LS in males. UV light treatment is recommended for extragenital LS; however, there is limited scientific evidence. Topical calcineurin inhibitors are second line treatment. Laser treatment, using various wave lengths, is under investigation, and it can currently not be recommended for the treatment of LS. Treatment with biologics is only reported in single cases. Conclusions: LS has to be diagnosed and treated as early as possible in order to minimize sequelae like scarring and cancer development. Topical potent and ultrapotent corticosteroids are the gold standard of care; genital LS is often a lifelong disease and needs to be treated long-term.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BALANITIS-XEROTICA-OBLITERANS; PLATELET-RICH PLASMA; CARBON-DIOXIDE LASER; ALLERGIC CONTACT-DERMATITIS; CLOBETASOL PROPIONATE 0.05-PERCENT; TOPICAL CALCINEURIN INHIBITORS; ACID PHOTODYNAMIC THERAPY; EPIDERMAL CD44 EXPRESSION; 5-YEAR FOLLOW-UP; ET-ATROPHICUS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 16 Jan 2026 07:40 |
| Last Modified: | 16 Jan 2026 07:40 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65412 |
Actions (login required)
 |
View Item |
